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Use of national data sources in diabetes epidemiology 
Health authorities worldwide have been collecting vast 
quantities of data for many years. Historically, such 
data—generally obtained for administrative, ﬁ nancial, 
and clinical reasons—have rarely been used for research 
because of problems with access, scale, and linkages. 
However, things are changing, with a move towards 
open data access, improved computing power, and a 
realisation by governments that routine data might be 
able to answer important health questions eﬃ  ciently 
and cost-eﬀ ectively if records are appropriately linked 
while maintaining anonymity. The UK, where patients 
can be traced from primary care consultations to death, 
oﬀ ers one of the world’s most promising sources of 
routine data in terms of research potential. The key 
issue is whether such data can be used to produce good-
quality research that is similar to, or even enhances, 
bespoke data collection. Up to now, evidence of this 
type of data being used in such a way to study diabetes 
has been scant, but this gap has now been addressed 
by Anoop Dinesh Shah and colleagues1 in The Lancet 
Diabetes & Endocrinology.  
The investigators have linked longitudinal data 
for almost 2 million people aged 30 years or older 
without previous cardiovascular disease, across 
general practices, hospitals, the national register of 
acute coronary syndromes, and death registrations 
in the CALIBER study.2 They analysed the relation 
between type 2 diabetes status (recorded as positive 
in 34 198 individuals in the cohort) and twelve initial 
manifestations of incident cardiovascular disease. This 
study is the ﬁ rst, of which I am aware, to look at subtypes 
of cardiovascular disease outcomes in such ﬁ ne detail. 
They report that peripheral arterial disease is the most 
common ﬁ rst presentation of cardiovascular disease 
for people with type 2 diabetes (reported in 992 [16%] 
of 6137 who had a cardiovascular event), and people 
with diabetes were almost three times as likely to have 
peripheral arterial disease as an initial presentation than 
were those without diabetes (10 074 [9%] of 107 501; 
adjusted HR 2·98 [95% CI 2·76−3·22]; p<0·0001). 
However, diabetes was not associated with sudden 
death, and was negatively associated with subarachnoid 
haemorrhage and abdominal aortic aneurysm, which 
provide intriguing contrasts with the other nine initial 
manifestations of cardiovascular disease analysed, all 
of which showed positive associations with diabetes. 
Importantly, the hazard ratios reported for other 
types of cardiovascular disease that are often analysed 
in clinical trials and observational epidemiology 
(ie, myocardial infarction and stroke) are broadly 
consistent with past cohort studies.3,4 Furthermore, 
the investigators’ data suggest that diabetes has more 
of an eﬀ ect on cardiovascular disease in young women 
than in young men, consistent with results of the 
most recent large meta-analyses.5,6 Finally, in line with 
large epidemiological studies,3,4 Shah and colleagues’ 
results show attenuation of the eﬀ ects of diabetes on 
cardiovascular disease with age. So the study not only 
shows that use of routine data can give sensible results, 
but also adds value in terms of ﬁ ne detail and precision 
(narrow conﬁ dence intervals).
The study’s results should be interpreted with 
caution. Unusually, the investigators analysed initial 
presentations rather than all manifestations of, for 
example, peripheral arterial disease. Most researchers 
would include, in presentations of risk and relative risk, 
peripheral arterial disease events that came after other 
cardiovascular disease events. This limitation makes 
direct comparisons with earlier studies, including those 
in the preceding paragraph, approximate. However, 
since the risk of having several cardiovascular disease 
events is not high, the approximation should be 
quite accurate. Whether or not this method gives 
a more reasonable estimate of the true eﬀ ect of 
diabetes, unencumbered by intervention after another 
cardiovascular disease event, is debatable—hazard ratios 
for diabetes might be expected to be lower than with 
the usual all-events method, because of the greater risk 
of most competing cardiovascular disease events in 
individuals with diabetes. 
Shah and colleagues have shown that careful 
processing of routinely obtained linked national health 
data, and not a little hard labour,2 can produce an 
excellent basis for aetiological research.7 Their study 
suggests that the limited quality of routine data—
including incomplete event ascertainment and missing 
data—can be overcome in observational analyses. The 
question remains as to how the new epidemiological 
results on subsets of cardiovascular disease outcomes 
in diabetes might aﬀ ect practice. As the investigators 
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Many studies have attempted to quantify the eﬀ ect 
of obesity on death, fueling a sustained controversy 
about which levels of bodyweight can harm health.1 
However, many investigators have argued that life 
expectancy does not capture the essence of the 
damage that obesity causes across a lifetime and 
that better long-term metrics are needed to convey 
risk, judge interventions, and motivate behaviour.2 
In The Lancet Diabetes & Endocrinology, Steven Grover 
and colleagues3 model the eﬀ ect of diabetes and 
cardiovascular disease in people who are overweight 
or obese and show what is intuitively known, but not 
often quantiﬁ ed, about obesity—that its eﬀ ect on the 
number of number of healthy-years lost is far greater 
than its eﬀ ect on total years of life. 
Constructing a model from cohort studies about the 
probability of transition to diabetes, cardiovascular 
disease, and death, Grover and colleagues’3 study 
used data for obesity, blood pressure, glucose 
concentrations, lipid concentrations, and other risk 
factors from 3992 non-Hispanic white participants 
from the US National Heath and Nutrition 
Examination Surveys 2003–10 to estimate the life 
years and healthy life-years lost associated with 
diﬀ erent levels of overweight and obesity. 
Among young adults aged 20–39 years, obesity 
(BMI 30–35 kg/m²) reduced healthy life-years by 
11·8 years (95% CI 9·9–13·7) in men and 14·6 years 
(12·0–17·2) in women, and reduced life expectancy 
by 5·9 years (4·4–7·4) in men and 5·6 years (4·1–7·1) 
in women. Among young adults aged 20–39 years, 
being very obese (BMI >35 kg/m²) reduced healthy 
life-years by 18·8 years (95% CI 16·8–20·8) in men 
and 19·1 years (16·7–21·5) in women, and shortened 
male life expectancy by 8·4 years (7·0–9·8) and female 
life expectancy by 6·1 years (4·6–7·6). On the basis 
of available life tables, these data mean that from 
young adulthood, obese and very obese people will 
spend a quarter to a third of their remaining lives with 
diabetes or cardiovascular disease. Being overweight 
(BMI 25–30 kg/m2) was also associated with small but 
signiﬁ cant reductions in healthy life-years, probably 
because of this BMI category’s strong association 
with diabetes. These ﬁ ndings are generally consistent 
with previous studies showing that young adults 
who are obese have more than a 50% lifetime risk of 
imply, new clinical trials in diabetes should now consider 
including (at least) peripheral arterial disease as part 
of any composite cardiovascular disease outcome, as 
should cardiovascular disease risk scores for people 
with diabetes.8 The varying levels and directions of 
association for diﬀ erent initial manifestations of 
cardiovascular disease might well prompt readers to 
instigate new research. 
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 Obesity, diabetes, and the moving targets of healthy-years 
estimation
